Trial Site Detail

 

Drug:
CB-839 + Talazoparib
Trial:
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Conditions: Solid Tumors
Trial Status:
Terminated

 

Carbone Cancer Center, University of Wisconsin

     
Madison , WI 53792
USA

 

Principal Investigator:
 Hamid Emamekhoo, MD
Contact:
 www.uwhealth.org/uw-carbone-cancer-center/cancer-connect/10310 608-262-5223
Activation Status of this Site:
 Closed
Notes about this Site:
Carbone Cancer Center, University of Wisconsin Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.